Alnylam Pharmaceuticals, Inc. (0HD2.L) LSE
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 52.7B |
| Enterprise Value | 54.23B |
| P/E Ratio | 65.69 |
| PEG Ratio | 0.03 |
| Price/Sales Ratio | 8.92 |
| Price/Book Ratio | 35.39 |
| Enterprise/Revenue | 8.82 |
| Enterprise/EBITDA | 40.89 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | March 31, 2026 |
Profitability
| Profit Margin | 0.13 |
| Operating Margin | 0.18 |
AD
Management Effectiveness
| Return On Assets | 0.11 |
| Return On Equity | 0.98 |
Income Statement
| Revenue | 3.71B |
| Revenue/Share | 32.26 |
| Gross Profit | 3.03B |
| EBITDA | 557.24M |
| Net Income | 313.75M |
| Diluted EPS | 2.33 |
Balance Sheet
| Total Cash | 3.01B |
| Total Cash/Share | 22.64 |
| Total Debt | 2.97B |
| Total Debt/Equity | 1.18 |
| Current Ratio | 3.13 |
| Book Value Per Share | 8.09 |
Price History
| 52-Week Change | -10.1 |
| 52-Week High | 288 |
| 52-Week Low | 143.66 |
| Moving Average 50 Days | 170.73 |
| Moving Average 200 Days | 180.79 |
Statistics
| Average Volume | 1,441 |
| Shares Outstanding | 133.51M |
| % Held by Institutions | N/A |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
AD
